Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.38 |
| ▸ | ESR1 | P03372 | 4/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14286456 | 0.87 | HSP90AA1 (0.38) | HSP90AA1ESR1HSD11B1HTR2CMPO | |
| SCHEMBL420051 | 0.87 | HSP90AA1 (0.37) | HSP90AA1ESR1HSD11B1HTR2CHSP90AB1 | |
| SCHEMBL8930902 | 0.85 | GAA (0.34) | HSP90AA1HTR2CMPOCYP19A1 | |
| SCHEMBL420960 | 0.83 | HSP90AA1 (0.35) | HSP90AA1ESR1HSD11B1 | |
| SCHEMBL1148483 | 0.82 | ESR1 (0.37) | HSP90AA1ESR1HTR2CMPOCCR4 | |
| SCHEMBL1305168 | 0.81 | CSNK1D (0.32) | MPO | |
| SCHEMBL442579 | 0.80 | HSP90AA1 (0.38) | HSP90AA1HSD11B1HSP90AB1 | |
| SCHEMBL419121 | 0.80 | HSP90AA1 (0.35) | HSP90AA1ESR1HSD11B1 | |
| SCHEMBL443458 | 0.80 | HSP90AA1 (0.33) | HSP90AA1HSD11B1HSP90AB1 | |
| SCHEMBL16141494 | 0.79 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | claimed |
| US-20150099721-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-04-09 | — | — | US | claimed |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | claimed |
| EP-2849751-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2015-03-25 | — | — | EP | claimed |
| US-20140194388-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-10 | — | — | US | claimed |
| EP-2678014-A2 | PROSTATE CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2014-01-01 | — | — | EP | claimed |
| EP-2663305-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH PROTEASOME INHIBITORS | Synta Pharmaceuticals Corp. (US) | 2013-11-20 | — | — | EP | claimed |
| WO-2013170159-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-14 | — | — | WO | claimed |
| EP-2648708-A2 | COMBINATION FOR BREAST CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2013-10-16 | — | — | EP | claimed |
| EP-2616063-A1 | HSP90 INHIBITORS FOR TREATING NON-SMALL CELL LUNG CANCERS IN WILD-TYPE EGFR AND/OR KRAS PATIENTS | Synta Pharmaceuticals Corp. (US) | 2013-07-24 | — | — | EP | claimed |
| US-8034834-B2 | Method for treating proliferative disorders with HSP90 inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-11 | — | — | US | claimed |
| WO-2011049946-A1 | COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-04-28 | — | — | WO | claimed |
| US-7825148-B2 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2010-11-02 | — | — | US | claimed |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP | 2010-04-15 | — | — | US | claimed |
| EP-2054059-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-05-06 | — | — | EP | claimed |
| WO-2008021364-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2008-02-21 | — | — | WO | claimed |
| EP-1817295-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006055760-A9 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-21 | — | — | WO | claimed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | claimed |
| WO-2006055760-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099721-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | ROS1, RET, HSP90AB1 | HSP90AA1 4/4885ESR1 1521/4885HSD11B1 1155/4885 |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885ESR1 3546/4885HSD11B1 1108/4885 |
| US-20140194388-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885ESR1 3546/4885HSD11B1 1108/4885 |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885ESR1 1794/4885HSD11B1 3353/4885 |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885ESR1 3369/4885HSD11B1 555/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885ESR1 3993/4885HSD11B1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.